



## Molecular Partners to hold three poster presentations at AACR 2025

March 25, 2025

*Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with  $^{212}\text{Pb}$ , co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer*

*First preclinical data on second  $^{212}\text{Pb}$ -based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors*

*Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors*

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- [Molecular Partners](#) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will hold three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, IL.

### Details of the presentations:

#### **MP0712, the first anti-DLL3 $^{212}\text{Pb}$ Radio-DARPin (RDT) candidate for targeted radiotherapy of small cell lung cancer (SCLC)**

Session Category: Experimental and Molecular Therapeutics  
Session Title: Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies  
Session Timing: Sunday April 27 at 2:00pm - 5:00pm CST  
Location: Poster Section 16, Poster Board Number: 13  
Published Abstract Number: 346

#### **Development of $^{212}\text{Pb}$ -based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumors**

Session Category: Experimental and Molecular Therapeutics  
Session Title: Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies  
Session Timing: Sunday April 27 at 2:00 – 5:00pm CST  
Location: Poster Section 16, Poster Board Number: 6  
Published Abstract Number: 339

#### **Next-generation multi-specific and conditionally activated CD3 Switch-DARPin with CD2 co-stimulation to tackle the current limitations of T cell engagers in solid tumors**

Session Category: Experimental and Molecular Therapeutics  
Session Title: Therapeutic Approaches to Attack the Tumor Microenvironment  
Session Timing: Monday April 28 at 2:00pm – 5:00pm CST  
Location: Poster Section 24, Poster Board Number: 3  
Published Abstract Number: 3119

### About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit [www.molecularpartners.com](http://www.molecularpartners.com) and find us on LinkedIn and Twitter/X [@MolecularPartners](#)

### For further details, please contact:

Seth Lewis, SVP Investor Relations & Strategy  
Concord, Massachusetts, U.S.  
[seth.lewis@molecularpartners.com](mailto:seth.lewis@molecularpartners.com)  
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications  
Zurich-Schlieren, Switzerland  
[laura.jeanbart@molecularpartners.com](mailto:laura.jeanbart@molecularpartners.com)  
Tel: +41 44 575 19 35

### Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024

offering. These statements may be identified by words such as "aim", "anticipate", "expect", "guidance", "intend", "outlook", "plan", "potential", "will" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at [www.molecularpartners.com](http://www.molecularpartners.com). In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.